Medical technology can leave a Miami laboratory with promising results and still face several separate commercialization problems. Who owns the invention? What can a licensee obtain? What evidence supports the intended use? Which regulatory pathway applies? Treating a patent application as the answer to all four questions creates avoidable confusion between scientific progress and a business ready to develop a product.

This article brings together University of Miami materials, two peer-reviewed studies, and federal guidance. Our original contribution is a comparison of evidence gaps and a staged commercialization framework. We have not evaluated any Miami device, conducted clinical research, or measured local licensing success. The examples explain how a team could organize its own review.

Miami’s research-to-market handoff

A University of Miami Medicine feature describes technology transfer as connecting scientific work with commercial partners, IP rights, and agreements. It identifies support from technology transfer, the Coulter Center, and other university programs. The useful local lesson is that commercialization involves several roles, rather than a researcher simply handing a patent to a manufacturer.

The university’s research policies also address inventions and intellectual property arising within its research environment and advise contacting technology transfer before publishing potentially protectable innovation. A researcher should review the applicable policy and agreements rather than assume that academic authorship determines commercial ownership.

Our practical recommendation is to begin with a rights map. List the institution, researchers, sponsors, outside collaborators, and materials or datasets used. Beside each name, identify the agreement or policy that needs review. Mark unknowns explicitly. This map is an administrative starting point, not a legal conclusion about who owns a particular invention.

Two studies, two views of public evidence

A 2024 npj Digital Medicine scoping review examined 692 AI medical-device summaries. It reported that 46.1% provided detailed performance-study results, while 1.9% linked to a scientific publication with safety and efficacy information. These findings concern the public documentation examined by the authors, not a finding that the remaining devices had never been tested.

Our calculation from those reported percentages is a 44.2 percentage-point difference between detailed results and linked publications: 46.1 minus 1.9. This is a contrast between two reporting indicators, not a measure of device safety or a count of unpublished studies. The categories should not be treated as mutually exclusive or combined into a clinical quality score.

A 2025 npj Digital Medicine study examined 1,012 summaries and reported an average transparency score of 3.3 across seventeen categories. Dividing 3.3 by 17 gives approximately 19.4% of the possible score. That normalization is our calculation; it is not a percentage of safe devices, successful patents, or validated products.

The studies use different samples and measures, so we do not interpret their numbers as a year-to-year deterioration or improvement. Together they motivate a narrower business question: can an outside reviewer understand the evidence supporting the product? Neither study measures the quality of Miami inventions or establishes the commercial value of a particular patent.

Public summaries have deliberate limits

The FDA’s AI-enabled device list explains that its public summaries are not all-inclusive and do not contain most information submitted in an application. The list itself is not comprehensive. Researchers and founders should therefore distinguish missing public detail from missing underlying evidence.

For a licensing team, this means a public search is the beginning of diligence. Ask what additional information can be shared under appropriate arrangements, which claims it supports, and whether the relevant product version matches the available evidence. Keep a record of what was reviewed and what remains unavailable rather than treating a database entry as a complete dossier.

Our original three-track commercialization framework

We propose keeping three parallel tracks visible throughout development. Each has a different decision maker and evidence packet. The framework is our analytical tool, not a regulatory checklist or a substitute for advice on a specific device.

A promising result on one track does not complete the others. A company may have an attractive license opportunity but an unresolved development plan. It may have a functioning prototype but incomplete rights from a collaborator. A patent document may describe an implementation that differs from the product now being tested. These are hypothetical examples of mismatches to investigate.

The framework helps meeting participants ask precise questions. Instead of saying the technology is ready, specify ready for what: an invention review, a licensing discussion, a development study, or a customer demonstration. That language reduces the chance that a scientific milestone will be mistaken for a legal or commercial conclusion.

Patents and permission to commercialize

The USPTO’s ownership guidance explains that a patent provides exclusionary rights and does not itself confer a right to practice the invention. Other patents or legal requirements can still matter. For a medical technology company, patent strategy, freedom-to-operate review, and regulatory advice therefore answer different questions.

Our recommended project brief names those assignments separately. Ask what technical features the proposed filing addresses, what product and territories any clearance work will cover, and which regulatory assumptions are outside the patent engagement. Separating scope early also makes budgets easier to interpret and prevents a favorable filing discussion from being oversold internally.

Plan publication and collaboration together

A Miami research team might be preparing a conference abstract while discussing a startup license and a sponsored development project. Our suggested planning method is a shared calendar of proposed disclosures, agreement reviews, and technical milestones. The calendar should identify a responsible person for each decision, with enough lead time to obtain advice before a document becomes public.

Material and data transfers deserve their own review. The University of Miami has specifically offered training on material transfer agreements and intellectual property in translational research. The operational lesson we draw is to track what arrives with restrictions, what leaves the institution, and which later uses require permission.

For the hypothetical team, the same sample may support a publication, a prototype, and a commercial discussion. Those uses should not automatically be treated as interchangeable. Keep the relevant permissions with the technical records so a future licensee does not have to reconstruct the history from scattered email exchanges.

Build a license discussion around a development plan

A prospective licensee needs more than a list of application numbers. Explain the problem addressed, the intended product, the evidence obtained, and the next experiment or engineering step. Distinguish what has been demonstrated from what remains a hypothesis. Describe which rights or know-how are available for discussion and which questions require institutional approval.

Our proposed one-page development brief has four parts: current evidence, next milestone, resources required, and a decision rule. For example, a team could specify what a bench test must establish before funding a later stage. This is an illustrative management method, not a recommendation about study design or patient care.

Link the brief to the rights map. If the next milestone requires a collaborator’s dataset or a contractor’s code, identify that dependency before promising delivery. A technically ambitious plan becomes more credible when it acknowledges the permissions, personnel, and agreements needed to execute it.

Keep an evidence revision history

A commercialization packet should identify the product version associated with each result. If the algorithm, materials, hardware, or intended workflow changes, record that change beside the relevant evidence. This does not determine whether additional testing or a regulatory submission is required; it gives qualified reviewers the facts needed to assess that question.

Our suggested register contains a document date, responsible person, product version, supported statement, and unresolved limitation. A licensing team can then trace an assertion back to the material actually reviewed. For a university collaboration, this also helps distinguish the original research result from development subsequently performed by a commercial partner.

Consider a hypothetical prototype whose sensor changes between a laboratory experiment and a partner demonstration. The earlier experiment may remain informative, but its applicability should be evaluated rather than assumed. A revision history makes the difference visible. It supports better questions about the next milestone without pretending that an administrative register validates a device. The same discipline improves discussion of patent descriptions, know-how, and the scope of materials proposed for a license. Keep the register accessible to authorized reviewers.

Make uncertainty reviewable

The central opportunity for Miami medtech teams is to make scientific, legal, and commercial uncertainty visible early. Public research can show where reporting is thin, university materials can identify relevant processes, and professional advice can address the actual invention and agreements. None alone provides a complete commercialization decision.

Before the next licensing conversation, assemble a rights map, disclosure calendar, evidence summary, and development brief. Those four documents give each participant a concrete starting point. They also make it easier to identify what additional review is necessary before the technology moves from a promising result toward a product.